Table 2 Demographics for the discovery cohort for proteomics analysis
| Â | Plaque disruption | No plaque disruption |
|---|---|---|
Number (male) | 10 (7) | 10 (5) |
Age [years (SD)] | 66 (8) | 67 (12) |
Acute coronary syndrome [n (%)] | 5 (50) | 6 (60) |
Smoking status [n (%)] | ||
 Current smoker | 1 (10) | 1 (10) |
 Past history of smoking (>1 month) | 7 (70) | 4 (40) |
 Never smoked | 2 (20) | 5 (50) |
Past History of IHD [n (%)] | ||
 MI/ACS | 2 (20) | 5 (50) |
 Stable angina | 4 (40) | 0 (0) |
Hypertension [n (%)] | 6 (60) | 8 (80) |
Hypercholesterolemia [n (%)] | 8 (80) | 6 (60) |
Diabetes mellitus [n (%)] | 0 (0) | 0 (0) |
Family history of IHD [n (%)] | 6 (60) | 5 (50) |
Regular medication [n (%)] | ||
 Aspirin | 6 (60) | 8 (80) |
 Thienopyridine | 3 (30) | 4 (30) |
 Statin | 7 (70) | 9 (70) |
 β-blocker | 5 (50) | 6 (50) |
 ACE inhibitor/ARB | 6 (60) | 7 (60) |
Plasma lipid profile | ||
 Total cholesterol [mmol/L (SD)] | 3.7 (0.4) | 3.8 (1.39) |
 HDL [mmol/L (SD)] | 1.0 (0.3) | 0.9 (0.3) |
 LDL [mmol/L (SD)] | 2.0 (0.3) | 2.3 (1.0) |
 Triglyceride [mmol/L (SD)] | 1.5 (0.7) | 1.5 (0.6) |